We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.

Delisted

BLPH was delisted on the 13th of October, 2023.

15 hedge funds and large institutions have $35.6M invested in Bellerophon Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

25% less funds holding

Funds holding: 2015 (-5)

39% less capital invested

Capital invested by funds: $58.6M → $35.6M (-$23M)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
15
Holders Change
-5
Holders Change %
-25%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
3
Increased
4
Reduced
4
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
NMVA
1
New Mountain Vantage Advisers
New York
$25.2M +$25M +323,992 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$6.76M
BBA
3
Baker Bros. Advisors
New York
$1.83M +$15.1K +196 +0.8%
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$682K +$184K +2,386 +37%
Vanguard Group
5
Vanguard Group
Pennsylvania
$454K +$156K +2,020 +53%
BIT
6
BlackRock Institutional Trust
California
$216K
LPL Financial
7
LPL Financial
California
$143K +$173K +2,252 New
Morgan Stanley
8
Morgan Stanley
New York
$95K -$102K -1,321 -52%
BG
9
BlackRock Group
United Kingdom
$76K -$5.62K -73 -7%
Goldman Sachs
10
Goldman Sachs
New York
$53K -$12.9K -167 -20%
UBS Group
11
UBS Group
Switzerland
$33K +$29.4K +382 +888%
Citigroup
12
Citigroup
New York
$7K +$7.09K +92 New
Bank of America
13
Bank of America
North Carolina
$6K
BIM
14
BlackRock Investment Management
Delaware
$4K
TRCT
15
Tower Research Capital (TRC)
New York
$1K -$770 -10 -43%
SIG
16
Senator Investment Group
New York
-$2.53M -21,266 Closed
HCMT
17
Highland Capital Management (Texas)
Texas
-$1.1M -9,260 Closed
CCA
18
Catalyst Capital Advisors
New York
-$912K -7,667 Closed
SM
19
Sabby Management
Florida
-$283K -2,382 Closed
Deutsche Bank
20
Deutsche Bank
Germany
-$20K -171 Closed
Canada Life
21
Canada Life
Manitoba, Canada
-$8K -70 Closed
BA
22
BlackRock Advisors
Delaware
-$3K -24 Closed

BLPH Hedge Fund Activity: Q3 2015 in Review

15 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2015, worth a combined $35.6M — down 39% from $58.6M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BLPH and 3 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was New Mountain Vantage Advisers, opening a new position worth an estimated $25M. The largest seller was Senator Investment Group, exiting entirely with an estimated $2.53M sold.

  • 15 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2015, down from 20 in Q2 2015.
  • Funds reported $35.6M of Bellerophon Therapeutics, Inc. stock for Q3 2015, down 39% quarter-over-quarter.
  • 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q3 2015 and 7 closed out, a net change of -4 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q3 2015 was New Mountain Vantage Advisers, an estimated $25M added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q3 2015 was Senator Investment Group, an estimated $2.53M sold.

Based on aggregated 13F filings for Q3 2015.